Spotlighting Sofetabart Mipitecan, an ADC-Targeting Folate Receptor Alpha, in High Grade Ovarian Cancer
4:15 pm - Wednesday 10th March 2027
- Unlocking the preclinical and PSAR technology of Sofe-M
- Highlighting results from the first-in-human phase 1 study
- Advancing model informed drug development to inform Phase 3 dose